The growth of the global biologics safety testing market is
driven by factors such as the growth in the biologics and biosimilars markets,
growing concerns over cell culture contamination, and rising biopharmaceuticals
R&D activities and investments. In addition, emerging markets and
increasing biopharmaceutical outsourcing are expected to provide significant
growth opportunities for players in the Biologics safety testing market.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
The combination of complex molecules created using advanced
DNA technology in an organism's genes is called biological. Biologics are
advanced drugs used to treat cancer, cardiovascular, rheumatoid arthritis and
other diseases.
Market Segmentation
Based on test type, the biologics safety testing
market is segmented into residual host-cell proteins and DNA detection tests,
endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, and virus
safety tests. the residual host-cell proteins and DNA detection tests segment
accounted for the largest market share.
Based on application, the biologics safety testing
market is segmented into monoclonal antibodies manufacturing, vaccines
manufacturing, blood and blood products manufacturing, cellular and gene
therapy products manufacturing, and other applications. the monoclonal
antibodies manufacturing segment accounted for the largest market share.
Regional Analysis
The Asia Pacific market is projected to witness the highest
growth rate during the forecast period, primarily due to the expansion of key
market players in emerging Asia Pacific countries, increasing expenditure on
life science research, and the increasing trend of pharmaceutical outsourcing
to Asia Pacific countries.
Key Market Players
Prominent players in the biologics safety testing market are
Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher
Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China),
and Eurofins Scientific (Luxembourg). The key players in this market are
focusing on strategic expansions, partnerships, and product launches and
approvals to expand their presence in the market.
Expected Revenue Growth:
The global biologics safety testing market is projected to
reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4%
during the forecast period.
CHARLES RIVER LABRATORIES (US)
Charles River is one of the key players in the biologics
safety testing market, it is a service and early-stage contract research
organization (CRO). The company develops a diverse portfolio of discovery and
safety assessment services and provides a suite of products and services to
support its clients’ manufacturing activities.
Frequently Asked Questions (FAQ):
What is the current size of the Biologics safety testing
market?
Who are the leading players in the biologics safety testing
market?
What are the major drivers of the biologics safety testing
market?
What is the COVID-19 impact on the biologics safety testing
market?
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com